Cardiac Drug Discovery

Innovate Your Approach to Drug Discovery

Dynamic and intricate monitoring of the excitation-contraction process of cardiomyocytes

The 5-year mortality rate for the over 23 million heart failure (HF) patients remains high, despite extensive efforts in development and investigation of therapeutic agents for the management HF. The physiological benefits of the treatments have often been coupled with unwanted side effects. Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) offer an exciting new model system to test both the efficacy and toxicity of new therapeutic approaches, including inotropic compounds which serve to modulate the force of cardiomyocyte contractility.

Assessment of Inotropic Compounds

Inotropic assays and other ex vivo whole organ assays are labor intensive, low throughput, and expensive. Alternatively, animal studies can also be conducted, but the actual predictivity of these assays and their translational potential to humans needs to be taken into account. Human iPSC-CM can provide a relevant model system for assessment of inotropic compounds. However, because of the relative immaturity of hiPSC-CM, assessment of inotropic compounds remain a challenge. ACEA Biosciences has developed an electrical pacing protocol which functionally matures hiPSC-CM (see maturity) enabling assessment of positive and negative inotropic compounds. Below is a summary table of inotropic compounds tested with electrically paced and functionally matured hiPSC-CM.

Figure 1: Summary of contractile responses of long-term electrically paced iCell CM2s to a panel of inotropic compounds, including 6 positive inotropes (+) and 1 negative inotrope (-)

Overcome hurdles in your research to find your next insight of compounds effecting the contractile process

Test Alt

Webinar: Evaluating Drug Induced Proarrhythmic Risk Using the CardioECR System

Dr. Haoyu Zeng describes his experience using the CardioECR system to screen drugs as part of the FDA CiPA initiative.

Watch Webinar
Jason Maynes Video

Webinar: Exploring the Role of iPSC-Cardiomyocytes in Drug Discovery and Safety Assessment

Dr. Kristina Green (Myokardia) and Dr. Armando Lagrutta (Merck) will describe new approaches aimed at enhancing assessment of hiPSC-CM functionality.

Watch Webinar
Test Alt

Publication: High throughput physiological screening of iPSC cardiomyocytes for drug development

A review of emerging technologies for high throughput measurements of cardiomyocyte physiology, and comments on using iPSC cardiomyocytes to model disease & drug discovery. 

Read More

Easy and Flexible Work Flow: Simply plate the cells, start acquiring data, and perform combination treatments & chronic dosing

Simplify your analysis – powerful software to help you elucidate information from data
Unique software monitors integrated ion channel activity, contractility, and longer term viability to elucidate adverse compound action.

Click to Learn More

 

See What Real-Time Cell Analysis Does For You

The xCELLigence CardioECR® system combines real-time impedance monitoring with both multielectrode array (MEA) technology and a pacing function for the evaluation of cardiomyocyte function along with integrated ion channel activity.

Click to Learn More

The xCELLigence® RTCA Cardio system uses non-invasive, label-free impedance monitoring to quantitatively evaluate cardiomyocyte health/function in real-time.

Click to Learn More

 

Are your hiPSC-CMs displaying neonatal gene expression profile? The xCELLigence RTCA CardioECR system has a powerful electrical pacing capability which can be used to functionally mature hiPSC-CM which display more adult-like functional profile and a more organized calcium handling machinery.

Click here to learn more


Training and Webinars

ACEA Biosciences offers webinars and free online training to help you find your next breakthrough

View WebinarsView App Notes

 

 


ACEA Biosciences – The Cell Analysis Company

At ACEA Biosciences, our goal is to apply innovative technologies to the analysis of cellular mechanism and response, making studies possible that were not even imaginable just a few years ago. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet our customers’ needs by delivering innovative, flexible, and scalable solutions to advance the next breakthrough in elucidating mechanisms of the human body. ACEA real-time cell analysis and flow cytometry technologies are fueling groundbreaking advancements in life science research and molecular diagnostics.